Clinical Trial: A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07652658) titled 'A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.' on May 05.

Brief Summary: This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.

Study Start Date: June 15

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis (IPF)

Intervention: OTHER: Placebo for AZD8965

Placebo for AZD8965

DRUG: AZD8965 low dose

AZD8965 low dose

DRUG: AZD8965 medium dose

A...